

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIEN TECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

**(1) CHANGE OF JOINT COMPANY SECRETARIES,
PROCESS AGENT AND AUTHORISED REPRESENTATIVE; AND
(2) WAIVER FROM STRICT COMPLIANCE WITH
RULES 3.28 AND 8.17 OF THE LISTING RULES**

CHANGE OF JOINT COMPANY SECRETARY, PROCESS AGENT AND AUTHORISED REPRESENTATIVE

The board (the “**Board**”) of directors (the “**Directors**”) of LPU ScienTech Medical Technology with its (Shanghai) Co., Ltd.* (the “**Company**”) and its subsidiaries (collectively, the “**Group**”) announces that (1) Mr. Qin Xue (“**Mr. Qin**”) has resigned as the joint company secretary of the Company (the “**Joint Company Secretary**”) due to adjustment of work arrangement with effect from October 22, 2026. Mr. Qin will continue to act as the Deputy General Manager and Chief Financial Officer of the Group; and (2) Ms. Yeung Lai Shan (“**Ms. Yeung**”) has resigned as (i) the other Joint Company Secretary, (ii) agent for the service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) as required under Rule 19A.13(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and (iii) authorised representative (the “**Authorised Representative**”) pursuant to Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and Rule 3.05 of Listing Rules due to adjustment of work arrangement, with effect from October 22, 2026.

Each of Mr. Qin and Ms. Yeung has confirmed that they have no disagreement with the Board and there are no matters relating to their resignations that needs to be brought to the attention of the Stock Exchange and/or the shareholders of the Company.

The Board is pleased to announce that Mr. Chen Ming (“**Mr. Chen**”) has been appointed as the Joint Company Secretary with effect from October 22, 2026 and Ms. Ma Ho Ki (“**Ms. Ma**”) has been appointed as (i) the Joint Company Secretary, (ii) the Process Agent and (iii) the Authorised Representative, with effect from October 22, 2026.

The biographical details of Mr. Chen are set out as follows:

Mr. Chen is currently the Board secretary of the Company. He oversees the investor relations, corporate governance, and information disclosure functions of the Company. He is primarily responsible for strategic communication, stakeholders engagement and regulatory compliance of the Company. He is also responsible to organize and prepare for all of the Board meetings, board committee meetings, shareholders’ meetings, and take an active role in promoting good corporate governance practices such as periodic evaluation on the effectiveness of internal control system of the Group in respect of design and operation as well as ensuring compliance with relevant laws and regulations applicable to the Company.

Prior to joining the Company, Mr. Chen accumulated extensive experience in the healthcare sector, capital markets and regulatory compliance through his work in the securities industry and public sector.

Mr. Chen possesses diversified experience in equity research, capital markets, corporate governance, accounting and regulatory affairs. Mr. Chen obtained Bachelor's degree in Accounting from the School of Management of Fudan University in June 2016 and Master's degree in Finance from The Hong Kong University of Science and Technology in June 2022. He is also a holder of the Chinese Certified Public Accountant (CICPA) qualification.

The biographical details of Ms. Ma are set out as follows:

Ms. Ma is currently a Manager of Company Secretarial Services of Tricor Services Limited, a global professional services provider specializing in integrated business, corporate and investor services. She has over 10 years of experience in the corporate secretarial field. Ms. Ma is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rule 8.17 of Listing Rules, a listed issuer must appoint a company secretary who satisfies the requirements under Rule 3.28 of the Listing Rules. Pursuant to Rule 3.28 of the Listing Rules, a listed issuer must appoint as its company secretary an individual who, by virtue of his/her academic or professional qualifications or relevant experience, is, in the opinion of the Stock Exchange, capable of discharging the functions of company secretary.

The Company considers that Mr. Chen, by virtue of his academic qualifications, familiarity with the Company's operations as well as experience in handling its compliance with listing requirements and corporate governance matters and with the support to be rendered by Ms. Ma, who fully complies with the requirements as stipulated under Rule 3.28 of the Listing Rules and her working team at Tricor Services Limited, would be capable of discharging his functions as a Joint Company Secretary.

The Company believes that it would be in the best interests of the Company and the corporate governance of the Group to have as its joint company secretary a person such as Mr. Chen, who is an employee of the Company and who has day-to-day knowledge of the Company's affairs. Mr. Chen has the necessary nexus to the Board and close working relationship with management of the Company in order to perform the function of a joint company secretary and to take the necessary actions in the most effective and efficient manner.

Through his extensive interactions with listed companies, institutional investors and various market participants throughout his career, as well as in his capacity as the Board Secretary of the Company, Mr. Chen has actively participated in the Company's strategic communications, stakeholder engagement and regulatory compliance matters, thereby acquiring extensive knowledge of the relevant Hong Kong regulatory requirements.

In relation to the appointment of Mr. Chen as Joint Company Secretary and since he does not possess the qualifications of company secretary as required under Rule 3.28 of the Listing Rules, the Company has applied for, and the Stock Exchange has granted, a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period of three years from the effective date of the appointment of Mr. Chen as a Joint Company Secretary (the “**Waiver Period**”).

The waiver is granted on the conditions that (i) Mr. Chen must be assisted by Ms. Ma during the Waiver Period; and (ii) the waiver could be revoked if there is any material breach of the Listing Rules by the Company. In addition, the Company should announce the reasons for, details and conditions of this waiver and the qualification and experience of both Mr. Chen and Ms. Ma. Before the end of the Waiver Period, the Company must demonstrate and seek the Stock Exchange’s confirmation that Mr. Chen, having had the benefit of Ms. Ma’s assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The waiver applies to the appointment of Mr. Chen as the Joint Company Secretary only. The Stock Exchange may withdraw or change the waiver if the Company’s situation changes.

The Board wishes to take this opportunity to express its gratitude to Mr. Qin and Ms. Yeung for their contribution during their tenure of offices and express its warmest welcome to Mr. Chen and Ms. Ma for taking up the appointments.

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People’s Republic of China
October 22, 2026

As at the date of this announcement, the Board comprises Ms. Chen Juan as executive Director, Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zhu Guanfu as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name “LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.”.*

For identification purposes only